key Takeaways
- Finerenone may offer significant blood pressure management benefits in heart failure patients.
- The drug could potentially reduce the frequency of outpatient worsening heart failure events.
- Patients with higher BMI might experience enhanced efficacy from finerenone treatment.
- Initial eGFR decline might serve as a predictor for positive long-term outcomes with finerenone.
Bayer is set to showcase new findings from the Phase III FINEARTS-HF trial, focusing on finerenone’s impact on heart failure patients with a left ventricular ejection fraction of 40% or higher. The presentation will take place at the Cardiovascular Clinical Trials Forum in Washington, D.C., from December 9-11, 2024.
During the two-day event, Bayer will present several critical analyses. These include evaluating finerenone’s effects on systolic blood pressure, its role in reducing outpatient worsening heart failure events, and its impact across different patient subgroups categorized by ejection fraction levels and body mass index (BMI). Additionally, the analyses will cover the initial decline in estimated glomerular filtration rate (eGFR) associated with finerenone and its efficacy in frail heart failure patients.
Comprehensive Pooled Data Insights
A significant portion of the presentation will focus on a participant-level pooled analysis across three Phase III clinical trials. This analysis aims to provide a broader understanding of finerenone’s safety and effectiveness in treating heart failure with mildly reduced or preserved ejection fraction.
The data presented will contribute to the growing body of evidence supporting finerenone’s role in managing heart failure, particularly in populations with specific clinical characteristics. These insights are expected to inform future treatment guidelines and enhance patient care strategies.
Finerenone, marketed as Kerendia or Firialta, is a non-steroidal mineralocorticoid receptor antagonist approved for treating chronic kidney disease associated with type 2 diabetes. Although not yet approved for heart failure, these new analyses could pave the way for expanded indications.
Bayer’s commitment to cardiovascular and kidney diseases emphasizes their dedication to addressing unmet medical needs through innovative treatments. The FINEARTS-HF study is a part of their extensive FINEOVATE program, which includes multiple Phase III trials aimed at evaluating finerenone’s efficacy and safety across various conditions.
Advancements in heart failure treatment are crucial as the global population ages, and the prevalence of cardiovascular diseases rises. Bayer’s ongoing research and presentations at forums like CVCT 2024 demonstrate their role in driving these medical advancements forward.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
